$880.83
-9.85[-1.11%]
Last update: 9:29AM Get Real Time Here
Regeneron Pharmaceuticals
(NASDAQ:REGN)Latest News for Regeneron Pharmaceuticals Stock (NASDAQ:REGN)
Regeneron Pharmaceuticals Stock (NASDAQ: REGN)
Categories: All
Thursday, April 25, 2024
- AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head StudyVandana Singh - 23 hours ago
- Regeneron, Mammoth Partner To Pursue Next-Generation CRISPR-Based Gene Editing For Multiple Diseases; Mammoth To Receive $100M Total Upfront Payment And Equity InvestmentBenzinga Newsdesk - 1 day ago
Wednesday, April 24, 2024
Monday, April 22, 2024
Thursday, April 18, 2024
Wednesday, April 17, 2024
- Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His PickVandana Singh - Apr 17, 2024, 2:39PM
- If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 TodayBenzinga Insights - Apr 17, 2024, 1:00PM
- Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $925 Price TargetBenzinga Newsdesk - Apr 17, 2024, 9:25AM
Monday, April 15, 2024
Friday, April 12, 2024
Thursday, April 11, 2024
Tuesday, April 09, 2024
Wednesday, April 03, 2024
Monday, April 01, 2024
Thursday, March 28, 2024
Tuesday, March 26, 2024
Monday, March 25, 2024
- FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial ConcernsVandana Singh - Mar 25, 2024, 11:50AM
- Regeneron shares are trading lower after the FDA issued Complete Response Letters for the company's Biologics License Application for odronextamab. The company said the only approvability issue is related to the enrollment status of the confirmatory trials.Benzinga Newsdesk - Mar 25, 2024, 7:44AM
- Regeneron Says FDA Issued Complete Response Letters For Biologics License Application For Odronextamab In Relapsed/Refractory (R/R) Follicular Lymphoma And R/R Diffuse Large B-cell LymphomaBenzinga Newsdesk - Mar 25, 2024, 7:02AM
Friday, March 22, 2024
Wednesday, March 20, 2024
Friday, March 15, 2024
Wednesday, March 13, 2024
Tuesday, March 12, 2024
Monday, March 11, 2024
- Bernstein Initiates Coverage On Regeneron Pharmaceuticals with Outperform Rating, Announces Price Target of $1125Benzinga Newsdesk - Mar 11, 2024, 4:44PM
- Regeneron Announces FDA Has Extended The Approval Of Praluent To Include Patients Aged 8 And Older With HeFHBenzinga Newsdesk - Mar 11, 2024, 7:02AM
Friday, March 08, 2024
Friday, March 01, 2024
Tuesday, February 27, 2024
Monday, February 26, 2024
Friday, February 23, 2024
Thursday, February 22, 2024
Wednesday, February 21, 2024
- Regeneron Pharmaceuticals Says Linvoseltamab BLA For Treatment Of Relapsed/Refractory Multiple Myeloma Accepted For FDA Priority Review, Target Action Date For FDA Decision Is August 22, 2024Benzinga Newsdesk - Feb 21, 2024, 7:16AM
- Regeneron Pharmaceuticals Says Linvoseltamab BLA For Treatment Of Relapsed/Refractory Multiple Myeloma Accepted For FDA Priority ReviewBenzinga Newsdesk - Feb 21, 2024, 7:10AM
Tuesday, February 20, 2024
Friday, February 16, 2024
Monday, February 12, 2024
Tuesday, February 06, 2024
- 4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts ForecastVandana Singh - Feb 6, 2024, 2:05PM
- $100 Invested In This Stock 20 Years Ago Would Be Worth $6,400 TodayBenzinga Insights - Feb 6, 2024, 12:00PM
- Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To KnowBenzinga Insights - Feb 6, 2024, 12:00PM
- Cantor Fitzgerald Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $925Benzinga Newsdesk - Feb 6, 2024, 9:39AM